Form 4: Hims & Hers Director Granted Restricted Stock Units

Hims & Hers Health, Inc. director Deborah M. Autor received a grant of 3,656 Restricted Stock Units (RSUs) as part of her compensation.

Summary

• Deborah M. Autor, a Director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs were granted on August 6, 2025, with a transaction price of $0.
• The RSUs will vest subject to continuous service, on the earlier of the date of the 2026 annual meeting of stockholders or June 15, 2026.
• Following this transaction, Deborah M. Autor beneficially owns 3,656 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive event as it aligns the director's interests with the company's long-term performance and shareholder value. It is a standard compensation practice and does not indicate any negative operational or financial issues.

Positives

• The grant of Restricted Stock Units aligns the director's interests with those of the shareholders, as the value of the RSUs is tied to the company's stock performance.
• Equity compensation is a standard practice for compensating directors, promoting long-term commitment and performance.

Risks

• The vesting of the Restricted Stock Units is subject to the director's continuous service, meaning the RSUs could be forfeited if service terminates before the vesting date.

Future Outlook

The Restricted Stock Units are expected to vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026, contingent upon the director's continuous service.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the healthcare and technology sectors for executive and board compensation, aiming to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a standard practice across publicly traded companies, including those in the healthcare and telehealth industries, such as Teladoc Health (TDOC) or GoodRx (GDRX), which also utilize equity-based awards to incentivize and retain board members.
• The vesting schedule, tied to continuous service and a future date/event, is typical for such grants, ensuring long-term commitment from the director.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The Restricted Stock Units will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026, subject to continuous service.

Key Dates

Keywords

Hims & Hers Health, HIMS, Restricted Stock Units, RSU grant, Director compensation, SEC Form 4, Insider transaction, Equity compensation